Intelligent Bio Solutions Inc

Intelligent Bio Solutions, Inc. operates as a biosensor diagnostic technology company. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions" or the "Company") (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced that the Company has selected Human and Supplement Testing Australia ("HASTA"), Australia's largest independent sports drug testing laboratory, as its preferred drug testing specialist in Australia to complete lab-based confirmation testing for its Intelligent Fingerprinting System, which analyzes sweat to screen for recent drug use.

Intelligent Bio Solutions Inc. Selects HASTA Laboratory as Drug Testing Specialist in Australia

NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced the closing of its previously announced underwritten public offering of 654,990 shares of common stock and warrants to purchase up to 196,497 shares of its common stock at a combined public offering price of $3.90 per share of common stock and accompanying warrants, which included the full exercise of the underwriter's option to purchase up to 85,430 additional shares of common stock and additional warrants to purchase up to 25,629 shares of its common stock. Including the option exercise, the aggregate gross proceeds from the offering were approximately $2.55 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Intelligent Bio Solutions Inc. Announces Closing of $2.55 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares and Warrants

Intelligent Bio Solutions (NASDAQ: INBS ) stock is taking a beating on Wednesday after the company announced a proposed public stock offering. The company announced that offering yesterday, and then released details of the offering early this morning.

Why Is Intelligent Bio Solutions (INBS) Stock Down 48% Today?

NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced the pricing of its previously announced underwritten public offering of 569,560 shares of common stock and warrants to purchase up to 170,868 shares of its common stock at a combined public offering price of $3.90 per share of common stock and accompanying warrants, for initial gross proceeds of approximately $2.2 million, before underwriting discounts and commissions and offering expenses. The warrants have an exercise price of $3.90 per share, are exercisable immediately and will expire five years following the date of issuance.

Intelligent Bio Solutions Inc. Announces Pricing of $2.2 Million Public Offering

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the securities are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Intelligent Bio Solutions Inc. Announces Proposed Public Offering

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions" or the "Company") (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced that on February 27, 2023, the Company received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).

Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Listing Requirement

- 513(g) submission will allow Intelligent Bio Solutions Inc. to determine the most suitable FDA regulatory pathway for its Intelligent Fingerprinting Drug Screening Cartridge, as the next step in its expansion strategy into the U.S. -

Intelligent Bio Solutions Inc. files FDA 513(g) regulatory submission for Intelligent Fingerprinting Drug Screening Cartridge

- Second quarter total revenue and government support income increased over 100% year-over-year -

Intelligent Bio Solutions Inc. Reports Fiscal 2023 Second Quarter Financial Results and Operational Highlights

Kiora Pharmaceuticals

Lizhi

Innovative Eyewear Inc

Sidus Space

Seqll

Vaccinex Inc

Penny stocks to watch with news this month. The post 7 Penny Stocks To Watch With Big News In February; Time To Buy?

7 Penny Stocks To Watch With Big News In February; Time To Buy?

Boughey Distribution switches to Intelligent Fingerprinting for its faster end-to-end testing, non-invasive nature, and ability to conduct tests in-house Boughey Distribution switches to Intelligent Fingerprinting for its faster end-to-end testing, non-invasive nature, and ability to conduct tests in-house

Intelligent Bio Solutions Inc. Announces Leading Food Industry Logistics Provider to Implement Fingerprint Drug Testing, Replacing Urine Testing

Context Therapeutics LLC

Hillstream Biopharma

Rent the Runway

Silo Pharma Inc

Sonoma Pharmaceuticals

Spectrum Pharma

Penny Stocks With News Light Up The Scanners This Week This week

7 Top Penny Stocks To Watch With Big News This Week

Gardening Supplier, Hozelock, to Roll Out Hygienic and Non-Invasive Intelligent Fingerprinting for Drug Tests to Promote Employee Safety Gardening Supplier, Hozelock, to Roll Out Hygienic and Non-Invasive Intelligent Fingerprinting for Drug Tests to Promote Employee Safety

Intelligent Bio Solutions Inc. Announces Global Garden Equipment Manufacturer to Introduce Intelligent Fingerprinting Drug Tests

Grom Social Enterprises

Summit Wireless Technologies Inc

Should you use a short term penny stocks trading strategy? The post The Benefits of Short Term Trading Penny Stocks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The Benefits of Short Term Trading Penny Stocks

Genius Group Ltd

Helbiz

Use these tips to help make money with penny stocks in 2023 The post These Tips Could Make You Money With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Tips Could Make You Money With Penny Stocks

The stock price of Intelligent Bio Solutions (INBS) skyrocketed by 293.13% in the most recent trading session. This is why.

Why The Intelligent Bio Solutions Stock Skyrocketed 293.13% (INBS)

Intelligent Bio Solutions (NASDAQ: INBS ) stock is rocketing higher on Monday thanks to a new milestone for the biosensor company. As detailed in a press release, the development of Intelligent Bio Solutions' biosensor platform is going well.

Why Is Intelligent Bio Solutions (INBS) Stock Up 363% Today?

BiondVax Pharmaceuticals

Tritium DCFC Ltd

Ryvyl Inc

TScan Therapeutics

Penny stocks to watch with news that are turning heads in the stock market this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 To Watch After Big News This Week

Achieves Record 4x Improvement in Time-To-Result to Provide Test Results in Under 1 Minute Achieves Record 4x Improvement in Time-To-Result to Provide Test Results in Under 1 Minute

Intelligent Bio Solutions Reaches Key Milestone in Biosensor Platform Development

NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that it has closed a Regulation S private placement (the “Transaction”) for expected aggregate gross proceeds of $220,585.

Intelligent Bio Solutions Inc. Announces Closing of Private Placement Offering

Company Intends to Hold FY 2022 Annual Meeting in February 2023 Company Intends to Hold FY 2022 Annual Meeting in February 2023

Intelligent Bio Solutions Inc. Announces Cancellation of FY 2021 Annual Meeting of Stockholders

Intelligent Bio Solutions Inc. (NASDAQ:INBS ) Q1 2023 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Harry Simeonidis - Chairman and CEO Spiro Sakiris - Chief Financial Officer Philip Hand - Executive Chairman, Intelligent Fingerprinting Limited Conference Call Participants John Vandermosten - Zacks Operator Greetings. And welcome to the Intelligent Bio Solutions Inc. First Quarter 2023 Earnings Conference Call.

Intelligent Bio Solutions Inc. (INBS) Q1 2023 Earnings Call Transcript

- Acquired Intelligent Fingerprinting Limited and its proprietary drugs of abuse screening technology -

Intelligent Bio Solutions Inc. Reports First Quarter Ending September 30, 2022, Preliminary Financial Results and Recent Business Highlights

- Can now test 1,000 employees across six sites as required, with each test always taking only ten minutes - - Can now test 1,000 employees across six sites as required, with each test always taking only ten minutes -

Intelligent Bio Solutions Inc. (INBS) Announces UK-Wide Glass Manufacturer to Roll Out Non-Invasive Drug Screening System Across UK Operations

- Eastern Airways to use portable, hygienic, non-invasive fingerprint sweat test to support new European Aviation Authority regulations -

Intelligent Bio Solutions Inc. Announces Airline Adopts Fingerprint Drug Screening System for In-house Testing

- Company to Host Conference Call & Webcast at 4:30 p.m. ET - - Company to Host Conference Call & Webcast at 4:30 p.m. ET -

Intelligent Bio Solutions Inc. to Present First Quarter 2023 Financial Results and Recent Corporate Update on November 9

News for Intelligent Bio Solutions Inc Stock (INBS)